Kathy Giusti challenges the academic-research model for fighting cancer

At Harvard Business School class day, Multiple Myeloma Research Foundation founder Kathy Giusti speaks of challenging the academic-research model.

Kathy Giusti

Harvard Business School’s class day speaker, Kathy Giusti, M.B.A '85, a former alumni achievement award winner at the school, has turned her personal experience, following her diagnosis with multiple myeloma (a fatal cancer of the plasma cells) in 1996, into her new profession, as founder and CEO of the Multiple Myeloma Research Foundation (MMRF) and its sister organization, the Multiple Myeloma Research Consortium. The organizations, under Giusti’s leadership, have raised well over $100 million to promote research to address the disease.

In essence, Giusti has found a way to channel privately raised funding into targeted, focused research meant to accelerate the development, clinical testing, and approval for use of new treatments for her disease. Her business background (at Merck, Gillette and Searle), her M.B.A. training, and of course her personal situation have all driven her approach, which is now being emulated for other, similar causes.

Recanati professor of medicine Jerome E. Groopman (read the Harvard Magazine profile)—a hematologist and oncologist—in 2008 devoted one of his New Yorker medical columns, “Buying a Cure,” to Giusti and her business model. He quoted her as saying of the existing approach to medical research, “We’re still learning as we try to change the system. To understand how to cure patients, we are going to have to break down a very broken system.” Groopman agrees with that sentiment, to a degree: for diseases, like multiple myeloma, where the basic biology is relatively well understood, and where the economics of drug discovery are hampered by companies’ search for therapies that apply to larger patient populations.

But for basic biological research, where fundamental knowledge is still needed, he conveys some skepticism: “’Research is not just connecting the dots,’ a prominent scientist who receives funding from the foundation told me. ‘You need creative latitude.’” Groopman quoted Todd Golub, professor of pediatrics, who runs a foundation-funded myeloma genomics project in which the Broad Institute is a partner, as admiring Giusti for promoting notions of accountability, transparency, and collaboration, while also cautioning that researchers need to balance very applied science with more basic, exploratory inquiries: “You need to find the sweet spot between just lobbing money over the fence versus believing we know everything that needs to be done.”

Related topics

You might also like

Harvard President Alan Garber Helps First-Years Move In

As a potential settlement with the Trump administration looms, Garber gets students settled. 

Harvard’s New Online Orientation Emphasizes Intellectual Paths

A summer course for first-years focuses on academic success, diverse viewpoints.

The Pump Celebrates Its 85th Birthday

Giving Harvard traditions their due 

Most popular

Shakespeare’s Greatest Rival

Without Christopher Marlowe, there might not have been a Bard.

How MAGA Went Mainstream at Harvard

Trump, TikTok, and the pandemic are reshaping Gen Z politics.

How AI Could Be Raising Your Energy Bill

Utilities shift AI infrastructure costs onto consumers.

Explore More From Current Issue

Brandon Terry, wearing a blue suit, standing before The Embrace, a large bronze sculpture of intertwined arms in Boston Common.

A New Narrative of Civil Rights

Political philosopher Brandon Terry’s vision of racial progress

David McCord in suit reading a book at cluttered wooden desk in office filled with framed art and shelves.

The Pump Celebrates Its 85th Birthday

Giving Harvard traditions their due 

Man in gray sweater standing in hallway with colorful abstract art on wall.

How Do Single-Celled Organisms Learn and Remember?

A Harvard neuroscientist’s quest to model memory